Multiple vaccination including serogroup C Meningococcus
Various improvements to vaccines that include a serogroup C meningococcal conjugate antigen, including: (a) co-administration with acellular B. pertussis antigen; (b) co-administration with an inactivated poliovirus antigen; (c) supply in a kit together with a separate pneumococcal conjugate component, which may be in a liquid form; and (d) use in combination with a pneumococcal conjugate antigen but without an aluminum phosphate adjuvant. A kit may have: (a) a first immunogenic component that comprises an aqueous formulation of a conjugated capsular saccharide from Streptococcus pneumoniae ; and (b) a second immunogenic component that comprises a conjugated capsular saccharide from Neisseria meningitidis serogroup C.
1. A kit for immunizing a subject against both Streptococcus pneumoniae and Neisseria meningitidis serogroup C, comprising a first immunogenic component and a second immunogenic component, wherein: (a) the first immunogenic component comprises an aqueous formulation of a conjugated capsular saccharide from Streptococcus pneumoniae ; and (b) the second immunogenic component comprises a conjugated capsular saccharide from Neisseria meningitidis serogroup C.
2. The kit of claim 1 , wherein the second immunogenic component is an aqueous formulation.
3. The kit of claim 1 , wherein the second immunogenic component is a lyophilised formulation.
4. The kit of claim 1 , wherein the first or second immunogenic component also comprises one or more of: a diphtheria toxoid, a tetanus toxoid, Bordetella pertussis antigen(s), a hepatitis B virus surface antigen, an inactivated poliovirus antigen.
5. The kit of claim 2 , wherein the first or second immunogenic component also comprises one or more of: a diphtheria toxoid, a tetanus toxoid, Bordetella pertussis antigen(s), a hepatitis B virus surface antigen, an inactivated poliovirus antigen.
6. The kit of claim 3 , wherein the first or second immunogenic component also comprises one or more of: a diphtheria toxoid, a tetanus toxoid, Bordetella pertussis antigen(s), a hepatitis B virus surface antigen, an inactivated poliovirus antigen.
7. The kit of claim 4 , wherein (a) the first immunogenic component comprises each of: a diphtheria toxoid, a tetanus toxoid, Bordetella pertussis antigen(s), a hepatitis B virus surface antigen, and an inactivated poliovirus antigen; or (b) the second immunogenic component comprises each of: a diphtheria toxoid, a tetanus toxoid, Bordetella pertussis antigen(s), a hepatitis B virus surface antigen, and an inactivated poliovirus antigen; or (c) the kit comprises a third immunogenic component which comprises each of: a diphtheria toxoid, a tetanus toxoid, Bordetella pertussis antigen(s), a hepatitis B virus surface antigen, and an inactivated poliovirus antigen.
8. The kit of claim 7 , wherein the first or second or third immunogenic component also comprises a conjugated Haemophilus influenzae type b antigen.
9. The kit of claim 5 , wherein (a) the first immunogenic component comprises each of: a diphtheria toxoid, a tetanus toxoid, Bordetella pertussis antigen(s), a hepatitis B virus surface antigen, and an inactivated poliovirus antigen; or (b) the second immunogenic component comprises each of: a diphtheria toxoid, a tetanus toxoid, Bordetella pertussis antigen(s), a hepatitis B virus surface antigen, and an inactivated poliovirus antigen; or (c) the kit comprises a third immunogenic component which comprises each of: a diphtheria toxoid, a tetanus toxoid, Bordetella pertussis antigen(s), a hepatitis B virus surface antigen, and an inactivated poliovirus antigen.
10. The kit of claim 9 , wherein the first or second or third immunogenic component also comprises a conjugated Haemophilus influenzae type b antigen.
11. The kit of claim 6 , wherein (a) the first immunogenic component comprises each of: a diphtheria toxoid, a tetanus toxoid, Bordetella pertussis antigen(s), a hepatitis B virus surface antigen, and an inactivated poliovirus antigen; or (b) the second immunogenic component comprises each of: a diphtheria toxoid, a tetanus toxoid, Bordetella pertussis antigen(s), a hepatitis B virus surface antigen, and an inactivated poliovirus antigen; or (c) the kit comprises a third immunogenic component which comprises each of: a diphtheria toxoid, a tetanus toxoid, Bordetella pertussis antigen(s), a hepatitis B virus surface antigen, and an inactivated poliovirus antigen.
12. The kit of claim 11 , wherein the first or second or third immunogenic component also comprises a conjugated Haemophilus influenzae type b antigen.
13. The kit of claim 1 , wherein the first immunogenic component comprises capsular saccharides from more than one serotype of Streptococcus pneumoniae.
14. The kit of claim 1 , wherein the first immunogenic component comprises capsular saccharides for at least Streptococcus pneumoniae serotypes 6B, 14, 19F and 23F.
15. The kit of claim 13 , wherein the Streptococcus pneumoniae capsular saccharides are conjugated to a carrier protein.
16. The kit of claim 14 , wherein the Streptococcus pneumoniae capsular saccharides are conjugated to a carrier protein.
17. The kit of claim 15 , wherein the carrier protein is a tetanus toxoid carrier protein, a diphtheria toxoid carrier protein, a CRM197 carrier protein or a Haemophilus influenzae protein D carrier protein.
18. The kit of claim 16 , wherein the carrier protein is a tetanus toxoid carrier protein, a diphtheria toxoid carrier protein, a CRM197 carrier protein or a Haemophilus influenzae protein D carrier protein.
19. The kit of claim 15 , wherein multiple carrier proteins are used for mixed pneumococcal serotypes.
20. The kit of claim 16 , wherein multiple carrier proteins are used for mixed pneumococcal serotypes.
21. The kit of claim 16 , wherein the Streptococcus pneumoniae conjugates each have a saccharide:protein ratio (w/w) of between 1:10 and 10:1.
22. The kit of claim 16 , wherein the Streptococcus pneumoniae conjugates are each present at between 1 μg and 20 μg (measured as saccharide) per dose.
23. The kit of claim 1 , wherein the second immunogenic component comprises capsular saccharides from a OAc+ strain of Neisseria meningitidis serogroup C.
24. The kit of claim 23 , wherein the OAc+ strain is C11.
25. The kit of claim 1 , wherein the Neisseria meningitidis serogroup C capsular saccharide is conjugated to a carrier protein.
26. The kit of claim 25 , wherein the carrier protein is a tetanus toxoid carrier protein, a diphtheria toxoid carrier protein, a CRM197 carrier protein or a Haemophilus influenzae protein D carrier protein.
27. The kit of claim 25 , wherein the Neisseria meningitidis serogroup C conjugate has a saccharide:protein ratio (w/w) of between 1:10 and 10:1.
28. The kit of claim 25 , wherein the Neisseria meningitidis serogroup C capsular saccharide has a molecular weight of <100 kDa.
29. The kit of claim 1 , wherein the Neisseria meningitidis serogroup C conjugate is not adsorbed to an aluminium salt.